235 related articles for article (PubMed ID: 23969780)
1. Use of prolactin receptor antagonist to better understand prolactin regulation of pituitary homeostasis.
Ferraris J; Bernichtein S; Pisera D; Goffin V
Neuroendocrinology; 2013; 98(3):171-9. PubMed ID: 23969780
[TBL] [Abstract][Full Text] [Related]
2. Prolactin receptor antagonism in mouse anterior pituitary: effects on cell turnover and prolactin receptor expression.
Ferraris J; Boutillon F; Bernadet M; Seilicovich A; Goffin V; Pisera D
Am J Physiol Endocrinol Metab; 2012 Feb; 302(3):E356-64. PubMed ID: 22094470
[TBL] [Abstract][Full Text] [Related]
3. Prolactin induces apoptosis of lactotropes in female rodents.
Ferraris J; Zárate S; Jaita G; Boutillon F; Bernadet M; Auffret J; Seilicovich A; Binart N; Goffin V; Pisera D
PLoS One; 2014; 9(5):e97383. PubMed ID: 24859278
[TBL] [Abstract][Full Text] [Related]
4. Prolactin receptor antagonism uncouples lipids from atherosclerosis susceptibility.
van der Sluis RJ; van den Aardweg T; Reuwer AQ; Twickler MT; Boutillon F; Van Eck M; Goffin V; Hoekstra M
J Endocrinol; 2014 Sep; 222(3):341-50. PubMed ID: 25063756
[TBL] [Abstract][Full Text] [Related]
5. Autocrine actions of prolactin contribute to the regulation of lactotroph function in vivo.
Bernard V; Lamothe S; Beau I; Guillou A; Martin A; Le Tissier P; Grattan D; Young J; Binart N
FASEB J; 2018 Sep; 32(9):4791-4797. PubMed ID: 29596024
[TBL] [Abstract][Full Text] [Related]
6. Structural and thermodynamic bases for the design of pure prolactin receptor antagonists: X-ray structure of Del1-9-G129R-hPRL.
Jomain JB; Tallet E; Broutin I; Hoos S; van Agthoven J; Ducruix A; Kelly PA; Kragelund BB; England P; Goffin V
J Biol Chem; 2007 Nov; 282(45):33118-31. PubMed ID: 17785459
[TBL] [Abstract][Full Text] [Related]
7. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies.
Standing D; Dandawate P; Anant S
Front Endocrinol (Lausanne); 2022; 13():1112987. PubMed ID: 36714582
[TBL] [Abstract][Full Text] [Related]
8. Differences in prolactin receptor (PRLR) in mouse and human fallopian tubes: evidence for multiple regulatory mechanisms controlling PRLR isoform expression in mice.
Shao R; Nutu M; Weijdegård B; Egecioglu E; Fernandez-Rodriguez J; Tallet E; Goffin V; Ling C; Billig H
Biol Reprod; 2008 Oct; 79(4):748-57. PubMed ID: 18596217
[TBL] [Abstract][Full Text] [Related]
9. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
[TBL] [Abstract][Full Text] [Related]
10. The many faces of prolactin in breast cancer.
Chen WY
Adv Exp Med Biol; 2015; 846():61-81. PubMed ID: 25472534
[TBL] [Abstract][Full Text] [Related]
11. [Prolactin (PRL)--multifunctional, hypophyseal peptide hormone].
Michalik J; Bartoszewicz Z
Postepy Biochem; 2002; 48(4):296-305. PubMed ID: 12731395
[No Abstract] [Full Text] [Related]
12. A major prolactin-binding complex on human milk fat globule membranes contains cyclophilins A and B: the complex is not the prolactin receptor.
Lorenson MY; Ueda EK; Chen KE; Walker AM
Am J Physiol Endocrinol Metab; 2012 Mar; 302(5):E585-94. PubMed ID: 22205628
[TBL] [Abstract][Full Text] [Related]
13. [Action mechanism of pituitary hormones--receptor and signal transduction--prolactin].
Aono T; Yokoyama Y
Nihon Rinsho; 1993 Oct; 51(10):2631-5. PubMed ID: 8254931
[TBL] [Abstract][Full Text] [Related]
14. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
15. Prolactin and the prolactin receptor: new targets of an old hormone.
Harris J; Stanford PM; Oakes SR; Ormandy CJ
Ann Med; 2004; 36(6):414-25. PubMed ID: 15513293
[TBL] [Abstract][Full Text] [Related]
16. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
Gutzman JH; Miller KK; Schuler LA
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
[TBL] [Abstract][Full Text] [Related]
17. JAK2/STAT5 Pathway Mediates Prolactin-Induced Apoptosis of Lactotropes.
de Dios N; Orrillo S; Irizarri M; Theas MS; Boutillon F; Candolfi M; Seilicovich A; Goffin V; Pisera D; Ferraris J
Neuroendocrinology; 2019; 108(2):84-97. PubMed ID: 30376668
[TBL] [Abstract][Full Text] [Related]
18. Prolactin receptor antagonists.
Kuo CB; Coss D; Walker AM
Endocrine; 1998 Oct; 9(2):121-31. PubMed ID: 9867245
[TBL] [Abstract][Full Text] [Related]
19. Development of new prolactin analogs acting as pure prolactin receptor antagonists.
Goffin V; Bernichtein S; Kayser C; Kelly PA
Pituitary; 2003 Sep; 6(2):89-95. PubMed ID: 14703018
[TBL] [Abstract][Full Text] [Related]
20. Prolactin stimulates cell proliferation through a long form of prolactin receptor and K+ channel activation.
Van Coppenolle F; Skryma R; Ouadid-Ahidouch H; Slomianny C; Roudbaraki M; Delcourt P; Dewailly E; Humez S; Crépin A; Gourdou I; Djiane J; Bonnal JL; Mauroy B; Prevarskaya N
Biochem J; 2004 Feb; 377(Pt 3):569-78. PubMed ID: 14565846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
